Elisa Ferrer
Biographic Data
| ID | 8980222 |
|---|---|
| NAME | Elisa Ferrer |
| GIVEN NAMES | Elisa |
| FAMILY NAME | Ferrer |
| SIGNATURE | FERRER E |
| AFFILIATIONS | EURORDIS‐Rare Diseases Europe Paris France |
| ORCID | 0009-0007-3888-2693 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2020 |
| LATEST PUBLICATION YEAR | 2021 |
| H-INDEX | 0 |
Evaluation of patient engagement in medicine development
BACKGROUND: Patient engagement is becoming more customary in medicine development. However, embedding it in organizational decision-making remains challenging, partly due to lack of agreement on its value and the means to evaluate it. The objective of this project was to develop a monitoring and evaluation framework, with metrics, to demonstrate impact and enhance learning. METHODS: A consortium of five patient groups, 15 biopharmaceutical compan…
Understanding multi‐stakeholder needs, preferences and expectations to define effective practices and processes of patient engagement in medicine development
BACKGROUND: The holistic evolution of patient engagement in medicines development requires a more detailed understanding of the needs of all involved stakeholders, and one that better accounts for the specific needs of some potentially vulnerable patient populations and key stages in medicines development. OBJECTIVE: The purpose of this convergent mixed-methods study was to better understand the needs of different stakeholders concerning patient …
Evaluating the “return on patient engagement initiatives” in medicines research and development
No prominent works on this page.
Evaluating the “return on patient engagement initiatives” in medicines research and development
Evaluation of patient engagement in medicine development
BACKGROUND: Patient engagement is becoming more customary in medicine development. However, embedding it in organizational decision-making remains challenging, partly due to lack of agreement on its value and the means to evaluate it. The objective of this project was to develop a monitoring and evaluation framework, with metrics, to demonstrate impact and enhance learning. METHODS: A consortium of five patient groups, 15 biopharmaceutical compan…
Understanding multi‐stakeholder needs, preferences and expectations to define effective practices and processes of patient engagement in medicine development
BACKGROUND: The holistic evolution of patient engagement in medicines development requires a more detailed understanding of the needs of all involved stakeholders, and one that better accounts for the specific needs of some potentially vulnerable patient populations and key stages in medicines development. OBJECTIVE: The purpose of this convergent mixed-methods study was to better understand the needs of different stakeholders concerning patient …
Business (3 works) · Computer Science (3 works) · Knowledge management (3 works) · Mental Health and Patient Involvement (3 works) · Political science (3 works) · Process management (3 works) · Psychology (3 works) · Public relations (3 works) · Medicine (2 works) · Patient-Provider Communication in Healthcare (2 works)